Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
To actively accelerate innovations to benefit patients, society, and the Dana-Farber Cancer Institute. We team with investigators to identify new discoveries and generate alliances to move science from bench to clinic for maximum impact.
To spark and fuel a spirit of innovation across the organization by providing effective tools to continuously question, create, and imagine what else might be possible.
In collaborating with Dana-Farber, your organization will have access to the Institute's specialized expertise, and to the unique array of core facilities needed to explore new areas of research. Learn more about Dana-Farber Centers that are interested in partnering with industry. Explore Dana-Farber's extensive Core Facilities. And discover more opportunities to collaborate.
In partnership with the Innovation Office, Dana-Farber makes publicly available a list of FDA-approved therapeutics and diagnostics in which the Institute has a financial interest. View the list
Contact Us Belfer Office for Dana-Farber Innovations10 Brookline Place, 3rd FloorBrookline, MA 02445 General Inquiry: innovation@dfci.harvard.edu Academic and/or Corporate MTAs: contractsteam@dfci.harvard.edu
Contact Us
Belfer Office for Dana-Farber Innovations10 Brookline Place, 3rd FloorBrookline, MA 02445
General Inquiry: innovation@dfci.harvard.edu
Academic and/or Corporate MTAs: contractsteam@dfci.harvard.edu
Nature Biotechnology recently named Dana-Farber's Loren D. Walensky, MD, PhD, a top translational researcher of 2019. Nature's nomination was based on total patents (European and US) granted for the year. Nature also shared that Dr. Walensky's top cited patent between 2015 and 2019 is US9273099, ‘Stabilized Alpha Helical Peptides And Uses Thereof’ with 23 total citations.
Dana-Farber investigators share in a new study a test that scans the activity of 70 genes in breast cancer tissue, which can help identify patients with invasive lobular carcinoma (ILC) who have a high risk of the cancer recurring or progressing after surgery. The findings, based on an international clinical trial known as MINDACT involving nearly 500 women with ILC, were presented by Dana-Farber's Otto Metzger, MD, at the European Breast Cancer Conference (EBBC) in October.
The National Academy of Medicine (NAM) has announced the election of Myles Brown, MD, Director of Dana-Farber's Center for Functional Cancer Epigenetics, during its annual meeting, alongside 90 regular members and 10 international members. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
Stay current with Dana-Farber technology news, transactions, patents, publications, events, and more.